GSK India Chief On Pandemic Decisions, Refreshing The Portfolio
GSK India managing director Sridhar Venkatesh outlines how the company navigated pandemic-related turbulence and “stuck its neck out” to ensure uninterrupted supplies of key drugs. The executive also discusses launch prospects for products including Xevudy in India and an intent to “refresh” the company’s vaccines portfolio.
You may also be interested in...
New developments on the COVID-19 front also include the European Medicines Agency starting a rolling review of Valneva’s investigational COVID-19 vaccine, and the UK government signing contracts with Pfizer/BioNTech and Moderna to buy more doses of their vaccines.
Sanofi India managing director N Rajaram and ex-GSK executive Salil Kallianpur discuss with Scrip a range of aspects around pharma’s digitization efforts including getting the "outside" talent mix right, avoiding digital "intrusion" in physician engagement and the impact of the surge in teleconsultation.
OPPI director general and ex-MSD India chief outlines how pharma in India is ensuring medicines reach patients amid COVID-19, working closely with various stakeholders. De-risking the supply chain and up-skilling sales forces in view of widespread digital engagement are among the key issues firms are addressing.